LITHIUM OROTATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C5H3N2O4.Li
Molecular Weight	162.029
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Li+].[O-]C(=O)C1=CC(=O)NC(=O)N1

InChI

InChIKey=IZJGDPULXXNWJP-UHFFFAOYSA-M

InChI=1S/C5H4N2O4.Li/c8-3-1-2(4(9)10)6-5(11)7-3;/h1H,(H,9,10)(H2,6,7,8,11);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	Li
Molecular Weight	6.941
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C5H3N2O4
Molecular Weight	155.0883
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.cpmedical.net/pdf/TS_CP7241_LithiumOrotate.pdf
Curator's Comment: description was created based on several sources, including: http://healthdarts.com/lithium-orotate/ | http://www.orthomolecularproducts.com/file.aspx?DocumentId=1667

Lithium orotate consists of lithium, an alkali metal, and orotic acid, a compound produced naturally in the body. Lithium orotate is marketed as a dietary supplement. It has a “GRAS” status. The chronic administration of lithium helps to support healthy mood by modulating NMDA receptors in the brain. Lithium also alters sodium transport and interferes with other ion exchange mechanisms, altering nerve conduction. Lithium can replace sodium in extracellular fluid. Recommended applications are: supports balanced mood; modulates polarization of cell membranes; ameliorates headaches; reduces alcohol cravings; supports healthy brain aging. Typical side effects are muscle weakness, apathy, loss of appetite (from all of one human trial).

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glutamate [NMDA] receptor 125 Target ID: CHEMBL2094124 Sources: http://www.cpmedical.net/pdf/TS_CP7241_LithiumOrotate.pdf	Modulator 828

Conditions

Condition	Modality	Highest Phase	Product
Alcoholism 19 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3718672	Primary	Approved 8429	Serenity Approved Use It is recommended to reduce alcohol cravings
Depression 235 Sources: https://nutritionreview.org/2013/04/lithium-orotate/	Primary	Approved 8429	Serenity Approved Use Lithium Orotate is used in certain patients with the mental depression.
Bipolar disorder 34 Sources: http://psycheducation.org/treatment/mood-stabilizers/the-big-three-for-bipolar-depression/lithium/lithium-orotate/	Primary	Approved 8429	Serenity Approved Use Lithium Orotate is used to treat mania that is part of bipolar disorder (manic-depressive illness).

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

Three to four capsules a day (120 mg in one capsule), taken in daily dosages with meals.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:15:37 GMT 2023` Edited by `admin` on `Fri Dec 15 16:15:37 GMT 2023`
Record UNII	L2N7Z24B30
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LITHIUM OROTATE

Common Name

English

Lithium orotate [WHO-DD]

Common Name

English

LITHIUM OROTATE [VANDF]

Common Name

English

4-PYRIMIDINECARBOXYLIC ACID, 1,2,3,6-TETRAHYDRO-2,6-DIOXO-, LITHIUM SALT (1:1)

Common Name

English

Classification Tree Code System Code

DSLD

499 (Number of products:145)